Arjan brings over 25 years of experience in the field of advanced therapies and Good Manufacturing Practices (GMP) operations, from early phase to commercial manufacture.
“Arjan is a great addition to the Achilles team,” said Dr Ed Samuel, SVP Technical Operations.“His in-depth knowledge and proven track record in manufacturing operations and product supply across multiple cell and gene therapy programmes will be invaluable as we expand our manufacturing capabilities to support the progress of our lead products through the clinic and broaden our pipeline into other solid tumour indications.”
“I am excited to be joining Achilles as the Company looks to potentially change how certain cancers are treated,” said Arjan Roozen. “I look forward to employing my experience in cell therapy manufacturing to scale out the Company’s manufacturing process capabilities, alongside meeting clinical development timelines in order to deliver groundbreaking therapies to patients.”
Arjan joins Achilles from Zelluna Immunotherapy where he was Chief Technology Officer responsible for GMP manufacturing for all product programmes and managing external contract laboratories. He also gained extensive cell therapy experience from his time at Cellectis where he was VP GMP Solutions/Manufacturing and involved in the company’s allogeneic CAR T programme. Prior to that, Arjan was at PharmaCell, a Netherlands-based cell and gene therapy contract manufacturer later acquired by Lonza Group AG, where he worked across multiple autologous and allogeneic therapies and, as the Operations Director, was responsible for GMP compliance and site performance. Arjan has a degree in microbiology with a specialisation in molecular microbiology.